Nektar Therapeutics Files 8-K with Material Agreement
Ticker: NKTR · Form: 8-K · Filed: Mar 4, 2024 · CIK: 906709
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
Related Tickers: NKTR
TL;DR
Nektar filed an 8-K for a material agreement and equity sales. Details to follow.
AI Summary
Nektar Therapeutics announced on March 4, 2024, that it entered into a Material Definitive Agreement. The company also disclosed unregistered sales of equity securities and filed financial statements and exhibits. Specific details regarding the agreement, the equity sales, and the financial statements were not provided in this initial filing.
Why It Matters
This filing indicates a significant event for Nektar Therapeutics, potentially involving new financing, partnerships, or strategic changes that could impact its future operations and stock value.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement and unregistered equity sales, which could signal significant corporate actions or financial needs that carry inherent risks.
Key Players & Entities
- Nektar Therapeutics (company) — Registrant
- March 4, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the Material Definitive Agreement entered into by Nektar Therapeutics?
The filing does not specify the details of the Material Definitive Agreement, only that one was entered into on or before March 4, 2024.
What type of equity securities were sold unregistered by Nektar Therapeutics?
The filing mentions unregistered sales of equity securities but does not provide specific details about the type or amount of securities sold.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on March 4, 2024.
What are the principal executive offices of Nektar Therapeutics?
The principal executive offices of Nektar Therapeutics are located at 455 Mission Bay Boulevard South, San Francisco, California 94158.
What is Nektar Therapeutics' Standard Industrial Classification code?
Nektar Therapeutics' Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,316 words · 5 min read · ~4 pages · Grade level 12.9 · Accepted 2024-03-04 08:40:59
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value NKTR Nasdaq Capital Marke
- $30.0 million — urities"), at a total purchase price of $30.0 million (or a purchase price of $1.20 per Warra
- $1.20 — f $30.0 million (or a purchase price of $1.20 per Warrant Share that can be issued up
- $30 m — ceeds for the Private Placement will be $30 million, before deducting expenses payabl
Filing Documents
- d762406d8k.htm (8-K) — 32KB
- d762406dex41.htm (EX-4.1) — 71KB
- d762406dex101.htm (EX-10.1) — 164KB
- 0001193125-24-056966.txt ( ) — 454KB
- nktr-20240304.xsd (EX-101.SCH) — 3KB
- nktr-20240304_lab.xml (EX-101.LAB) — 17KB
- nktr-20240304_pre.xml (EX-101.PRE) — 11KB
- d762406d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 4.1 Form of Pre-Funded Warrant 10.1* Securities Purchase Agreement, dated March 4, 2024, by and between Nektar Therapeutics and TCG Crossover Fund II, L.P. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEKTAR THERAPEUTICS Date: March 4, 2024 By: /s/ Mark A. Wilson Mark A. Wilson Chief Legal Officer and Secretary